Ofranergene obadenovec - VBL Therapeutics

Drug Profile

Ofranergene obadenovec - VBL Therapeutics

Alternative Names: GT-111; VB 111

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vascular Biogenics
  • Developer Gynecologic Oncology Group; Massachusetts General Hospital; VBL Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Angiogenesis modulating agents; Gene expression modulators; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma; Ovarian cancer
  • Phase II Thyroid cancer
  • Preclinical Lung cancer; Malignant melanoma

Most Recent Events

  • 08 Mar 2018 Primary endpoint was not met in the top-line efficacy data from the phase III GLOBE trial in Glioblastoma released by VBL Therapeutics
  • 27 Dec 2017 Phase-III clinical trials in Ovarian cancer (Second-line therapy or greater) in USA (IV)
  • 06 Nov 2017 Ofranergene obadenovec licensed to NanoCarrier in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top